News >

Expert Highlights Immunotherapy/Chemotherapy Combos in TNBC

Gina Columbus
Published: Wednesday, Oct 31, 2018

Lisa Carey, MD

Lisa Carey, MD
The efficacy of combination therapy with a checkpoint inhibitor and chemotherapy has been proved in the triple-negative breast cancer (TNBC) space, and the additive and early toxicity may be worth the survival benefit, Lisa A. Carey, MD, said in a presentation during the 2018 ESMO Congress.

Results of the phase III IMpassion130 trial, which were presented during the meeting, demonstrated that the addition of atezolizumab (Tecentriq) to nab-paclitaxel (Abraxane) reduced the risk of progression or death by 38% versus nab-paclitaxel alone in patients with PD-L1–positive metastatic TNBC.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication